ATS (ATS) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
19 Apr, 2026Strategic positioning and business overview
Operates as a decentralized automation and technology leader, providing end-to-end automation solutions across diverse industries and geographies.
Adjusted revenues reached C$2.9B (TTM), with a 13.4% five-year adjusted revenue CAGR and 13.8% adjusted EBITDA margin.
Major markets include life sciences (53% of revenue), food & beverage (17%), consumer products (16%), transportation (7%), and energy (7%).
Global footprint includes 65+ facilities, 85+ offices, operations in 20+ countries, and 7,500 employees.
Market focus and revenue breakdown
Life sciences generated $1,561M in adjusted revenue with a $1,090M order backlog; food & beverage, consumer products, transportation, and energy also contribute significantly.
Order backlog across all segments totals over $2B, supporting future revenue visibility.
Revenue mix has shifted toward services and recurring revenue, with a purposeful move away from custom integration.
Business model and operational excellence
The ATS Business Model (ABM) emphasizes performance management, strategic planning, and disciplined processes to drive growth.
Eight value drivers include bookings, revenue, EBIT margin, working capital, on-time delivery, quality, fill rate, and employee turnover.
Standardized performance measurement is applied across all business units.
Latest events from ATS
- Flexible shelf offering supports growth in automation for regulated, high-value markets.ATS
Registration filing27 Apr 2026 - Margin expansion, portfolio diversification, and disciplined M&A drive future growth plans.ATS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q3 revenue up 16.7%, net income surges, and strong backlog supports future growth.ATS
Q3 20264 Feb 2026 - Life sciences and nuclear energy drive growth, with disciplined M&A and resilient market focus.ATS
Raymond James 46th Annual Institutional Investors Conference3 Feb 2026 - Order bookings surged 18.4% as life sciences growth offset transportation softness.ATS
Q1 20252 Feb 2026 - Tripled revenue, tech innovation, and services expansion drive growth in life sciences and EV.ATS
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Strategic focus on regulated markets, M&A, and technology drives growth and innovation.ATS
15th Annual Global Materials & Industrials Conference31 Jan 2026 - Growth in life sciences and digital services, with GLP-1 and auto-injectors as key drivers.ATS
Jefferies Global Industrial Conference22 Jan 2026 - Q2 revenue fell 17% as life sciences bookings hit a record, offsetting transportation weakness.ATS
Q2 202516 Jan 2026